Article
Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study.
Diabetes care - 1 Jun 2004
Snitker Soren, Watanabe Richard M, Ani Ifeanyi, Xiang Anny H, Marroquin Aura, Ochoa Cesar, Goico Jose, Shuldiner Alan R, Buchanan Thomas A
Abstract excerpt
OBJECTIVE: We have tested whether the Pro12Ala variant of the peroxisome proliferator-activated receptor (PPAR)-gamma nuclear receptor involved in thiazolidinedione (TZD) action accounted for the failure of troglitazone to increase insulin sensitivity in nondiabetic Hispanic women with previous gestational diabetes treated in the Troglitazone in Prevention of Diabetes (TRIPOD) study. RESEARCH DESIGN AND METHODS:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.